Clinical trials establish therapeutic doses, but they rarely study the personalization that actually happens in practice
The GLP-1 category is approaching another important inflection point, driven mainly by the launch of oral therapies and the expansion of Medicare access in the U.S., says Terence Flynn, who leads coverage of U.S
2, Table 2) and stroke (RR 0.65 [95% CI 0.49, 0.86], low certainty of evidence due to risk of bias and inconsistency
As we continue to research and develop new treatments, I'm optimistic about our ability to help more people achieve a healthy weight and reduce their risk of obesity-related complications
Haq IU, Krukiewicz K, Tayyab H, et al
These differences matter clinically: larger average weight loss translates into bigger improvements in blood pressure, glycemic measures, sleep apnea metrics, mobility, and quality of life for many patients